HEALTH Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity Thursday, March 19, 2026 · rhythm pharmaceuticals, inc. Advertisement Read Original Article → Related Dispatches [US] · Jun 18 Ukraine Brings the War to Moscow as Huge Blasts Shake Refinery [US] · Jun 18 Death Toll From Israeli Fire in Gaza Since Ceasefire Passes 1,000, Says Health Ministry [US] · Jun 18 Macron's Versailles Diplomacy Wins Mixed Results Over Decade in Power